Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.10 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including other brain neurons; strongest in epicardial cells | 0.75 |
| chemistry Open Targets | compounds already reach it: samalizumab | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 26 Parkinson's papers of 1,223 | 0.57 |
| pathways Reactome | 1 pathway; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 2752
Sealed predictions
- CD200 in dopamine neurons, braak-0.03 (p 0.946) → -0.34 (p 0.378)receipt 2759
Swarm cases
receipt 2759: CD200 in dopamine neurons, braak
- power
- full sample -0.19 (p 0.439, n 18), 95% CI -0.61 to +0.30. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.21 (p 0.398, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.21 (p 0.403, n 18). could be the mix.
- skeptic
- leave-one-out range -0.35 to -0.12, sign flips 0; without severely affected donors -0.19 (p 0.439, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CD200 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts